Cognitive outcome of patients with classic infantile Pompe disease receiving enzyme therapy

Neurology

Volumn 78, Issue 19, 2012, Pages 1512-1518

  Ebbink, B J ^a   Aarsen, F K ^a   Van Gelder, C M ^a   Van Den Hout, J M P ^a   Weisglas Kuperus, N ^b   Jaeken, J ^a,d   Lequin, M H ^c   Arts, W F M ^a   Van Der Ploeg, A T ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b Division of Neonatology   (Netherlands)

^c Division of Radiology   (Netherlands)

^d UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE;

ARTICLE; BAYLEY SCALES OF INFANT DEVELOPMENT; CHILD; CLASSIC INFANTILE POMPE DISEASE; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COGNITION; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; ENZYME REPLACEMENT; FEMALE; GLYCOGEN STORAGE DISEASE TYPE 2; GRIFFITHS MENTAL DEVELOPMENT SCALE; GROWTH RETARDATION; HUMAN; HYPOTHALAMUS PERIVENTRICULAR NUCLEUS; INTELLIGENCE TEST; LANGUAGE DISABILITY; MALE; MENTAL DEVELOPMENT INDEX; MOTOR DYSFUNCTION; MOTOR PERFORMANCE; NEUROIMAGING; OUTCOME ASSESSMENT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; PSYCHOMOTOR DEVELOPMENT INDEX; QUADRIPLEGIA; SCHOOL CHILD; SCORING SYSTEM; SPEECH DISORDER; WECHSLER INTELLIGENCE SCALE; WHITE MATTER LESION;

EID: 84863630908     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/WNL.0b013e3182553c11     Document Type: Article

References (39)

1. Hirschhorn R, Reuser AJJ. Glycogen storage disease type II: acid alpha-glucosidase (acid maltase) deficiency. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill; 2001:3389-3420
2. Kishnani PS, Hwu WL, Mandel H, et al. A retrospective, multinational, multicenter study on the natural history of infantile-onset Pompe disease. J Pediatr 2006;148:671-676
3. Van den Hout JMP, Hop W, van Diggelen OP, et al. The natural course of infantile Pompe's disease: 20 original cases compared with 133 cases from the literature. Pediatrics 2003;112:332-340
4. Van der Ploeg AT, Reuser AJ. Pompe's disease. Lancet 2008;372:1342-1353
5. Van den Hout H, Reuser AJ, Vulto AG, Loonen MC, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human α-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356: 397-398
6. Amalfitano A, Bengur AR, Morse RP, et al. Recombinant human acid α-glucosidase enzyme therapy for infantile glycogen storage disease type II: results of a phase I/II clinical trial. Genet Med 2001;3:132-138
7. Kishnani PS, Corzo D, Nicolino M, et al. Recombinant human acid α-glucosidase: major clinical benefits in infantileonset Pompe disease. Neurology 2007;68:99-109
8. Chakrapani A, Vellodi A, Robinson P, Jones S, Wraith JE. Treatment of infantile Pompe disease with alglucosidase alpha: the UK experience. J Inherit Metab Dis 2010;33: 747-750
9. Kishnani PS, Corzo D, Leslie ND, et al. Early treatment with alglucosidase alfa prolongs long-term survival of infants with Pompe disease. Pediatr Res 2009;66:329-335
10. Begley DJ, Pontikis CC, Scarpa M. Lysosomal storage diseases and the blood-brain barrier. Curr Pharm Des 2008; 14:1566-1580
11. Martin JJ, de Barsy T, van Hoof F, Palladini G. Pompe's disease: an inborn lysosomal disorder with storage of glycogen: a study of brain and striated muscle. Acta Neuropathol 1973;23:229-244
12. Gambetti P, DiMauro S, Baker L. Nervous system in Pompe's disease: ultrastructure and biochemistry. J Neuropathol Exp Neurol 30:412-430, 1971
13. Mancall EL, Aponte GE, Berry RG. Pompe's disease (diffuse glycogenosis) with neuronal storage. J Neuropathol Exp Neurol 1965;24:85-96
14. Martini C, Ciana G, Benettoni A, et al. Intractable fever and cortical neuronal glycogen storage in glycogenosis type 2. Neurology 2001;57:906-908
15. Teng YT, Su WJ, Hou JW, Huang SF. Infantile-onset glycogen storage disease type II (Pompe disease): report of a case with genetic diagnosis and pathological findings. Chang Gung Med J 2004;27:379-384
16. Thurberg BL, Lynch Maloney C, Vaccaro C, et al. Characterization of pre- and post-treatment pathology after enzyme replacement therapy for Pompe disease. Lab Invest 2006;86:1208-1220
17. Chien YH, Lee NC, Peng SF, Hwu WL. Brain development in infantile-onset Pompe disease treated by enzyme replacement therapy. Pediatr Res 2006;60:349-352
18. Rohrbach M, Klein A, Köhli-Wiesner A, et al. CRIMnegative infantile Pompe disease: 42-month treatment outcome. J Inherit Metab Dis 2010;33:751-757
19. Van den Hout JM, Kamphoven JH, Winkel LP, et al. Long-term intravenous treatment of Pompe disease with recombinant human α-glucosidase from milk. Pediatrics 2004;113:e448-e457
20. Van der Meulen BF, Ruiter, SAJ, Lutje Spelberg HC, Smrkovský M. Bayley Scales of Infant Development Dutch Version, 2nd ed. Amsterdam: Pearson; 2002
21. Griffiths R. The Abilities of Babies, 2nd ed. Oxford, UK: The Test Agency Limited; 1986
22. Griffiths R. The Abilities of Young Children, 2nd ed. Oxford, UK: The Test Agency Limited; 1984
23. Kort W, Schittekatte M, Bosmans, EL, eds. Wechsler Intelligence Scale for Children, 3rd ed. Amsterdam: Pearson; 2005
24. Van Bon WHJ. Raven's Coloured Progressive Matrices: Dutch Norms and Other Research Outcomes, 1st ed. Amsterdam: Pearson; 1984
25. Raven JC. RAVEN: The Dutch Translation of the Manual of the Standard Version, 1st ed. Amsterdam: Pearson; 2006
26. Tellegen PJ, Winkel M, Wijnberg-Williams B, Laros JA. SON-R 21/2-7: Snijders Oomen Non-Verbal Intelligence Test-Revised, 1st ed. Amsterdam: Hogrefe; 2008
27. American Psychological Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Association; 2000
28. Neufeld EF, Muenzer J. The mucopolysaccharidosis. In: Scriver CR, Beadet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Bases of Inherited Disease, 8th ed. New York: McGraw-Hill; 2001:3421-3452
29. Vanier MT. Niemann-Pick disease type C. Orphanet J Rare Dis 2010;5:16
30. Hamdan MA, Almalik MH, Mirghani HM. Early administration of enzyme replacement therapy for Pompe disease: short-term follow-up results. J Inherit Metab Dis 2008;31(suppl 2):S431-S436
31. Kishnani PS, Nicolino M, Voit T, et al. Chinese hamster ovary cell derived recombinant human acid α-glucosidase in infantile onset Pompe disease. J Pediatr 2006;149:89-97
32. Winkel LPF, Kamphoven JHJ, van den Hout JMP, et al. Morphological changes in muscle tissue of patients with infantile Pompe's disease receiving enzyme replacement therapy. Muscle Nerve 2003;27:743-751
33. Filly CM. White matter: organisation and functional relevance. Neuropsychol Rev 2010;20:158-173
34. Njiokiktjien C. Behavioral Neurology of the Child, 1st ed. Amsterdam: Suyi; 2004
35. Northam GB, Liégeois F, Chong WK, Wyatt JS, Baldeweg T. Total brain white matter is a major determinant of IQ in adolescents born preterm. Ann Neurol 2011;69:702-711
36. Woodward LJ, Anderson PJ, Austin NC, Howard K, Inder TE. Neonatal MRI to predict neurodevelopmental outcomes in preterm infants. N Engl J Med 2006;355:685-694
37. Van Capelle CI, Goedegebure A, Homans NC, Hoeve HLJ, Reuser AJ, van der Ploeg AT. Hearing loss in Pompe disease revisited: results from a study of 24 children. J Inherit Metab Dis 2010;33:597-602
38. Van Gelder CM, van Capelle CI, Ebbink BJ, et al. Facialmuscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy. J Inherit Metab Dis Epub 2011 Oct 19
39. Muller CW, Jones HN, O'Grady G, Suárez AH, Heller JH, Kishnani PS. Language and speech function in children with infantile Pompe disease. J Pediatr Neurol 2009; 7:147-156.